{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060673","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.466830+00:00","generated_at":"2026-06-08T10:00:27.783827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cullinan Oncology reports Q3 net loss of $39.2M; cash runway extends to H2 2026","bullets":["Cash and investments $481.9M at Sept 30, 2023; runway extended into H2 2026 from prior into 2026, driven by $38M ATM net proceeds and higher interest income.","Net loss $39.2M in Q3 vs $32.2M in Q2; R&D expenses $33.8M (up from $27.4M) on higher manufacturing and clinical costs.","CLN-619 (MICA/B) monotherapy clinical activity observed; combination dose escalation enrollment completed; initial data expected Q2 2024.","Zipalertinib (EGFR ex20ins) Phase 2b REZILIENT1 enrollment completion targeted by end 2024; Phase 3 REZILIENT3 initiated.","CLN-978 (CD19xCD3) first patient dosed in Phase 1 for R/R B-NHL; CLN-617 first-in-human expected by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060673","json":"https://secwatch.observer/filing/0000950170-23-060673.json","markdown":"https://secwatch.observer/filing/0000950170-23-060673.md","text":"https://secwatch.observer/filing/0000950170-23-060673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/0000950170-23-060673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/cgem-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:00:27.783827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43118b0d5e581d38b0edfe02b84fb0ee2c135eee","claim":"Cullinan Therapeutics, Inc. updated its third quarter ended September 30, 2023 guidance (reaffirmed).","evidence_excerpt":"Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/0000950170-23-060673-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}